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Metabolomic Profiling to Dissect the Role of Visceral Fat
in Cardiometabolic Health
Cristina Menni1, Marie Migaud2, Craig A. Glastonbury1, Michelle Beaumont1, Aikaterini Nikolaou1, Kerrin S. Small1,
Mary Julia Brosnan3, Robert P. Mohney4, Tim D. Spector1, and Ana M. Valdes1,5
Objective: Abdominal obesity is associated with increased risk of type 2 diabetes (T2D) and cardiovas-
cular disease. The aim of this study was to assess whether metabolomic markers of T2D and blood pres-
sure (BP) act on these traits via visceral fat (VF) mass.
Methods: Metabolomic profiling of 280 fasting plasma metabolites was conducted on 2,401 women from
TwinsUK. The overlap was assessed between published metabolites associated with T2D, insulin resist-
ance, or BP and those that were identified to be associated with VF (after adjustment for covariates)
measured by dual-energy X-ray absorptiometry.
Results: In addition to glucose, six metabolites were strongly associated with both VF mass and T2D:
lactate and branched-chain amino acids, all of them related to metabolism and the tricarboxylic acid
cycle; on average, 38.5% of their association with insulin resistance was mediated by their association
with VF mass. Five metabolites were associated with BP and VF mass including the inflammation-
associated peptide HWESASXX, the steroid hormone androstenedione, lactate, and palmitate. On aver-
age, 29% of their effect on BP was mediated by their association with VF mass.
Conclusions: Little overlap was found between the metabolites associated with BP and those associ-
ated with insulin resistance via VF mass.
Obesity (2016) 24, 1380-1388. doi:10.1002/oby.21488
Introduction
Visceral obesity has been linked to insulin resistance, dyslipidemia,
and increased cardiovascular risk (1). Adipocytes in visceral fat
(VF) secrete numerous adipokines responsible for regulating differ-
ent physiological systems involved in energy homeostasis and endo-
crine and immune function (2), which are likely to determine the
link between higher VF mass and reduced cardiometabolic health or
increased risk of metabolic syndrome.
A number of metabolomic studies have examined associations
between metabolites and type 2 diabetes (T2D) (3-8) and between
metabolites and blood pressure (BP) regulation (9). Several amino
acids (isoleucine, leucine, valine, tyrosine, and phenylalanine)
plus other metabolites have been consistently associated with diabe-
tes (3-8). Metabolomic profiling of BP has also been carried out and
has found that a dicarboxylic fatty acid is functionally involved in
increased BP (9). Both increased BP and T2D are part of the meta-
bolic syndrome, and increased VF mass is a risk factor for both.
Excess VF is strongly associated with impaired suppression of free
fatty acid (FFA) release in response to insulin (2), as well as with
hypertriglyceridemia and low concentrations of high-density lipopro-
tein cholesterol. The high FFA concentrations in adipocytes and the
adipose tissue-resident macrophages result in more proinflammatory
cytokines, but less adiponectin. These cytokine changes induce
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insulin resistance in muscle and liver and play a major role in the
pathogenesis of endothelial dysfunction, a mechanism involved in
increased BP (10). Increased VF may also selectively affect hepatic
metabolism via greater portal vein FFA delivery (11). High levels of
FFA may also directly affect mitochondrial function and energy
metabolism, which are known to be impaired in T2D: when a long-
chain fatty acid enters a cell, a CoA group is added to the fatty acid
by fatty acyl-CoA synthase, forming long-chain acyl-CoA. The fatty
acid is then transported across the inner mitochondrial membrane.
The long-chain acyl-CoA enters the fatty acid b-oxidation pathway,
which results in the production of one acetyl-CoA from each
cycle of fatty acid b-oxidation. This acetyl-CoA then enters the
mitochondrial tricarboxylic acid (TCA) cycle (12). This overall
metabolic process is known to be dysfunctional in individuals with
T2D (13).
Metabolomic profiling of VF mass may help identify some of the
pathways underlying the metabolite associations found with T2D and
hypertension (HTN). We hypothesized that some of the metabolites
so far linked to T2D and BP by metabolomic profiling (3-9) may be
acting via VF mass and that they may reveal some of the molecular
pathways that are altered in individuals with high VF mass that give
rise to metabolic dysfunction resulting in T2D and high BP.
Methods
We analyzed data from 2,401 female twins from the TwinsUK
cohort for whom nontargeted metabolomics analysis was available
along with glucose/diabetic information, as well as VF measurement
via dual-energy X-ray absorptiometry (DXA) scans (14). All individ-
uals were used for all metabolomic versus VF analyses regardless of
their fasting glucose levels. The St. Thomas’ Research Ethics Com-
mittee approved the study (EC96/439 TwinsUK), and all participants
provided informed written consent.
VF measurement by DXA
Measurements of whole body composition were performed for 3,457
female twins aged 40 to 80 years using the DXA fan-beam technol-
ogy (Hologic QDR; Hologic, Inc., Waltham, MA). Subjects were
positioned in a standardized manner, in a supine position with the
clothes removed and wearing a gown. The DXA machine was cali-
brated on a daily basis using a spine phantom and on a weekly basis
using a step phantom, as suggested by the manufacturer. The scans
were analyzed using the QDR System Software Version 12.6.
Regions-of-interest were defined manually by the same operator fol-
lowing the Standard operating procedure (SOP), which was derived
from the manufacturer’s guidelines. The lower horizontal margins
were placed above the pelvis, just above the iliac crest, while the
upper horizontal margins were placed at the half of the distance
between the acromions and the iliac crest. The vertical margins
were adjusted just at the external borders of the body so that all the
soft tissue was included.
This DXA-based measurement of VF has been validated against VF
measured by CT scan (15) and shown to be reliable and reproduci-
ble. In a subset of 63 individuals from the TwinsUK cohort, we find
that the correlation between VF measured by DXA and by CT scan
is of 83% in line with published data.
Homeostasis model assessment-estimated insulin resistance
(HOMA-IR). Fasting insulin and glucose levels were measured for
the twin cohort using the same methods as previously described (16).
HOMA-IR was calculated by multiplying overnight fasting plasma
insulin (FPI) with overnight fasting plasma glucose (FPG), then divid-
ing by the constant 22.5, i.e. HOMA-IR5 (FPI3 FPG)/22.5 (17).
HTN and T2D definitions
T2D cases were defined as individuals with fasting glucose levels
7 mmol/L at time of initial sampling and at subsequent visits,
while T2D “super controls” were defined as subjects with fasting
glucose levels between 3.9 mmol/L and 5 mmol/L, as was done for
the original metabolomic study of T2D (5). HTN was defined using
the standard stage 1 cut-off systolic BP (SBP) 140 mm Hg or dia-
stolic BP (DBP) 90 mm Hg.
Metabolomics measurements
Nontargeted metabolite detection and quantification was conducted
by the metabolomics provider Metabolon, Inc. (Durham) on 2,401
fasting plasma samples from participants in the TwinsUK study, as
described previously (18). The metabolomic dataset measured by
Metabolon includes 280 known metabolites containing the following
broad categories—amino acids, acylcarnitines, sphingomyelins, glyc-
erophospholipids, carbohydrates, vitamins, lipids, nucleotides, pep-
tides, xenobiotics, and steroids.
Muther expression data
The Muther gene expression dataset included in this study consists
of 772 abdominal fat samples analyzed with the Illumina Human
HT-12 V3, as previously described (19).
Statistical analysis
Statistical analysis was carried out using Stata version 11. We
inverse-normalized the metabolomics data and excluded metabolic
traits with >20% missing values. Metabolite associations with VF
were assessed by random intercept linear regressions adjusted for
age, BMI, height (2), metabolite batch, DXA batch, and family
relatedness. We adjusted for multiple testing using Bonferroni cor-
rection resulting in a significant threshold of 1 3 1024.
We first tested the known metabolites we previously associated with
T2D (5) for correlation with VF. As VF is not only a risk factor for
T2D but has been also implicated in cardiovascular disease risk, we
used a stepwise backward regression model to identify a set of
metabolites that were significantly associated with VF using
P< 0.01 as cut-off threshold.
Association of selected metabolites with gene-expression levels in fat
were tested using random intercept linear regression adjusting for
age, BMI, metabolite batch, expression batch, and family relatedness.
Metabolite association mediated by VF
The proportion of the variance of the clinically relevant trait
(HOMA-IR or SBP) was first calculated explained for each metabo-
lite after taking into account all covariates (age, sex, BMI, height,
family relatedness, and metabolite batch). We call this quantity r2x .
The proportion of the variance for the same trait explained by the
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metabolite was then after taking into account the same covariates as
above but adjusting also for VF mass r2y . The percentage of
the metabolite association mediated by VF (r2y ) was calculated as
the proportion of the variance of the clinical trait that is due to the
metabolite’s association with VF, namely 1 - (r2x /r
2
y ).
Results
The descriptive characteristics of the study participants are pre-
sented in Table 1. The DXA measure of VF mass is strongly
associated with age, HOMA-IR, T2D, BP, and BMI (Table 1).
The strongest association is seen with BMI which is correlated
with VF mass with an r25 0.617. The unadjusted association with
T2D per standard deviation (SD) of VF mass (normalized) is
ORT2D [95% CI]5 3.01 [2.35-3.86]; P< 3.6 3 10
218. The associ-
ation remains significant after adjustment for BMI and age
(ORT2D5 2.02 [1.36-3.00]; P< 5.2 3 10
24). VF mass is also cor-
related with both systolic and diastolic BP and remains associated
with risk of HTN after adjustment for age and BMI
(ORHTN5 1.16 [1.02-1.30] P< 0.015).
We first investigated which metabolites are correlated with both
VF mass and T2D. Of the 28 known metabolites we previously
identified to be associated with T2D (5) (Figure 1 and Supporting
Information Table S1), seven of them including glucose and three
branched-chain amino acids (BCAAs) are also associated with VF
mass (after adjusting for multiple testing). At a nominal signifi-
cance level (P< 0.05), 16 of the 28 metabolites are associated
with both VF and T2D, and all of them except fructose and 4-
methyl 2-oxopentaoate are also associated with HOMA-IR (Figure
1 and Supporting Information Table S1). Twelve metabolites
associated with T2D, however, show no correlation with VF mass
(see Figure 1).
Metabolites associated with both T2D and VF
mass
Glucose, lactate, valine, leucine, isoleucine, 3-methyl-2-oxovalerate,
and 4-methyl-2-oxopentanoate are all associated with T2D and VF.
All these metabolites are associated with VF mass independently of
T2D status (Figure 1 and Table 2) and all these metabolites, except
glucose (which was not tested, being part of the definition of
HOMA-IR), remain significantly associated with VF mass after
adjusting for HOMA-IR and after adjustment for total fat mass. We
assessed whether the association between these metabolites and insu-
lin resistance was mediated by VF mass. On average, 38.5% of the
variance of HOMA-IR explained by the metabolites is accounted for
by the association with VF mass (Table 2). This value, however,
ranges from 19.4% for lactate to 61.3% for 4-methyl-2-
oxopentanoate.
All these metabolites are indirectly related to the TCA cycle and
metabolism. We assessed whether the expression of genes known to
be part of the TCA cycle in subcutaneous adipose tissue correlated
with VF mass. We selected human homologues for a list of TCA
genes reported originally for other organisms (20), which had probes
that passed quality control in our adipose tissue data. The probes
used mapped to citrate synthase (CS); aconitase 1 (ACO1); isocitrate
dehydrogenase 2 (IDH2); succinate dehydrogenase complex, subunit
A (SDHA); succinate dehydrogenase complex, subunit B (SDHB),
and succinate dehydrogenase complex, subunit C (SDHC) (20). The
results (Table 3) show a strong correlation between TCA gene
expression levels in fat biopsies and VF fat mass after adjusting for
age and BMI. No single gene from the TCA cycle is associated with
T2D, but adjusting for T2D makes the association with VF mass
disappear, suggesting a confounding effect for the association
between TCA cycle genes and T2D on fat mass. We also found that
these genes are correlated with metabolites that associate with both
VF and T2D.
TABLE 1 Demographic characteristics of the study population
Mean (SD) VF Q1 VF Q2 VF Q3 VF Q4
Associated
with VF mass,
P valuea
Visceral fat mass (g) 568. 2 (298.8) 1.28-332.7 332.8-523.0 532.1-753.4 753.5-1,725
Age (yr) 56.91 (11.57) 50.86 (12.75) 57.96 (11.33) 58.84 (10.40) 59.94 (9.313) 5 3 10259 b
BMI (kg/m2) 26.30 (4.90) 21.8 (2.20) 24.4 (2.41) 27.0 (3.08) 31.7 (4.77) 1 3 102300 c
Fasting HOMA-IR 0.98 (0.71) 0.56 (0.31) 0.73 (0.48) 0.99 (0.60) 1.50 (0.86) 3 3 10228 d
T2D cases: super controlse (%) 93:1,145 (8.1%) 8:297 (3%) 18:277 (6%) 9:254 (3%) 58:217 (21%) 0.000519 d
Systolic blood pressure (mm Hg) 127.4 (16.4) 119.4 (14.4) 126.4 (15.6) 130.2 (16.2) 133.5 (16) 2.14 3 1025 d
Diastolic blood pressure (mm Hg) 77.9 (9.6) 74.1 (9.1) 76.9 (9.1) 79.1 (9.3) 81.5 (9.6) 1.97 3 1029 d
Hypertension 21.9% 13.4% 18.5% 21.8% 33.7% 0.014 d
n 2,401 600 601 600 600
Female 100% 100% 100% 100% 100%
Data are presented as mean (SD) unless otherwise specified.
aP value for association between inverse normalized VF mass and continuous traits by linear or logistic regression adjusted for covariates.
bAdjusted for BMI.
cAdjusted for age.
dAdjusted for age and BMI.
eSuper controls are individuals with fasting glucose <5 mmol/L.
VF Q, quartiles of the visceral fat mass distribution in 2,401 individuals from the TwinsUK cohort; HOMA-IR, homeostasis model assessment-estimated insulin resistance
T2D, type 2 diabetes.
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Metabolites associated with T2D but not VF
mass
Not all the metabolites so far reported to be associated with T2D are
linked to VF mass; however, 12 metabolites including 8 lipids, 1 amino
acid related to inflammation and endothelial dysfunction (dimethyl
arginine), and 3 carbohydrates or metabolites of energy metabolism are
associated with T2D but not with VF. Ten of these 12 are associated
with a decreased risk of T2D (Figure 1). Of those associated with
Figure 1 Association of selected metabolites with (A) T2D, (B) visceral fat mass, and (C) homeostasis model assessment-estimated insulin resistance (HOMA-
IR). The metabolites are those previously reported to be associated with T2D with P< 0.0001. The odds ratio with T2D and the coefficients b and the 95%
confidence intervals of the linear regression with visceral fat mass and log HOMA-IR adjusted for covariates are shown for each metabolite. P values are
‡P< 0.0001, ¶0.0001 < P< 0.05, and n.s. P> 0.05.
TABLE 2 Proportion of the association of metabolites with insulin resistance and blood pressure that is mediated by their
association with VF mass
Metabolite name Trait
Metabolite
R2, no VF massa
Metabolite
R2, with VF massb
% Association
through VF mass
3-methyl-2-oxovalerate HOMA-IR 0.0126 0.0079 37.3
4-methyl-2-oxopentanoate HOMA-IR 0.0031 0.0012 61.3
Isoleucine HOMA-IR 0.0162 0.0111 31.5
Lactate HOMA-IR 0.0526 0.0424 19.4
Leucine HOMA-IR 0.0073 0.0039 46.6
Valine HOMA-IR 0.0181 0.0118 34.8
5a-androstan-3b, 17b-diol disulfate-1 SBP 0.01 0.0076 24.0
HWESASXX SBP 0.0041 0.0025 39.0
Lactate SBP 0.0033 0.0022 33.3
Palmitate SBP 0.0119 0.0105 11.8
Phenylacetylglutamine SBP 0.0035 0.0024 31.4
aThe proportion of the variance in HOMA-IR or SBP explained by the metabolite after taking into account all covariates (age, sex, BMI, height, and metabolite batch).
bThe proportion of the variance in HOMA-IR or SBP explained by the metabolite after taking into account the same covariates as in the first footnote and adjusting also for VF
mass.
HOMA-IR, homeostasis model assessment-estimated insulin resistance; VF, visceral fat; SBP, systolic blood pressure.
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decreased risk of T2D and not with insulin resistance, the most biologi-
cally interesting metabolites appear to be 1,5-anhydroglucitol, palmito-
leate [previously shown be elevated in fatty liver disease and to reflect
hepatic lipogenesis (21)], and dimethyl arginine.
Metabolites associated with VF mass and BP
In addition to the strong relationship with insulin resistance, VF
mass is also a marker for higher cardiovascular risk (22). We thus
carried a similar analysis comparing VF mass metabolites with those
we previously found associated with SBP and DBP (9) (Figure 2).
Four metabolites associated with increased BP are also associated
with higher VF mass: the inflammation-associated peptide HWE-
SASXX, the steroid hormone androstenedione, lactate, and palmi-
tate. One metabolite associated with lower BP, phenylacetylglut-
amine, was also associated with lower VF mass. As in the case of
T2D, all these associations remained essentially identical when we
adjusted for total fat mass. We also assessed how much of the asso-
ciation between these metabolites and BP was mediated by VF
mass. On average, 27.9% of the variance of SBP explained by the
metabolites is accounted for by the association with VF mass (Table
2), ranging from 11.8% for palmitate to 39.0% for HWESASXX.
Metabolites associated with VF mass but not
T2D
We examined significant metabolites associated with VF mass. We
identified 53 metabolites significantly associated with VF after
adjusting for covariates and multiple testing using Bonferroni cor-
rection. We analyzed, in a multivariate model, which of these
metabolites contributed independently, and we identified 20 inde-
pendent metabolites explaining 74% of the variance. As shown in
Table 4, many of these metabolites are not associated with T2D nor
BP. However, after adjusting for insulin resistance, only c-
tocopherol remains significantly associated with VF.
A summary of the results is presented in a Venn diagram, showing
the key metabolites associated with insulin resistance, VF, BP, and
T2D (Figure 3).
Discussion
In the present metabolomic study, we investigated which metabolites
associated with VF mass relate also to insulin resistance/T2D and
BP. We identified seven metabolites that strongly associated with
both T2D and VF mass and whose association with insulin resist-
ance appears to be in part mediated by VF mass. These include glu-
cose and three BCAAs. We also identified 12 metabolites (8 lipids,
one amino acid, 2 carbohydrates, and 1 intermediate of energy
metabolism) that show no correlation with VF mass despite their
strong association with T2D. Finally we identified five metabolites
in common between BP and VF mass.
Metabolites associated with both T2D and VF
mass
All the metabolites associated with both VF and T2D appear to be
related to central energy metabolism, which also regulates the intra-
cellular ratio of nicotinamide adenine dinucleotide hydrogenase/nic-
otinamide adenine dinucleotide levels. Lactate is produced fromTA
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pyruvate under anaerobic conditions with the concomitant oxidation
of NADH to NAD. The BCAAs valine, leucine, isoleucine are
essential amino acids (not synthesized by humans), hence their con-
centration in blood is caused by a lack of catabolism. BCAAs are
converted by transamination into BCKAs (23), two of which (3-
methyl-2-oxovalerate and 4-methyl-2-oxopentanoate) were also
increased in individuals with high VF mass. When energy metabo-
lism is properly functioning, these metabolites should be oxidised
via the mitochondrial branched-chain keto acid dehydrogenase com-
plex to CO2, NADH, and ultimately produce acetyl-CoA and
succinyl-CoA that enter the TCA cycle producing large mole to
mole equivalents of ATP (e.g. 39 moles ATP/mole leucine). How-
ever, the branched-chain keto acid dehydrogenase complex is subject
to feedback regulation (24), which explains the accumulation of
BCAAs and their metabolites. Other studies have previously shown
that BCAAs are significantly correlated with a metabolically unheal-
thy phenotype, and gene expression of BCAA catabolism and TCA
cycle-related genes are underexpressed in metabolically unhealthy
individuals compared to healthy subjects (25).
A reduced TCA cycle has been invoked as a maker of the diabetic
phenotype (26), and our data suggest that some of these disturbances
of the TCA cycle are mediated by VF mass. The gene expression
results presented here show a clear negative relationship between
genes encoding TCA cycle enzymes in adipose tissue and VF mass,
and this association goes away once we adjust for T2D. Since
abdominal obesity is modifiable, based on the current data we
hypothesize that reductions in VF mass should result in improved
TCA cycle efficiency in patients with T2D.
Metabolites associated with VF mass and BP
We identified four metabolites associated with increased BP and also
with higher VF mass: the inflammation-associated peptide HWE-
SASXX, the steroid hormone androstenedione, lactate, and palmitate.
On average 28.9% of their association with SBP appears to be medi-
ated by VF mass. (Table 2). We also identified one metabolite, phenyl-
acetylglutamine, associated with lower BP and lower VF mass.
Only lactate is associated with VF mass, insulin resistance, and BP.
Lactate’s metabolism is not only altered in obesity (27), but meta-
bolic shift to aerobic glycolysis, both in pulmonary vasculature and
the right ventricle is seen in pulmonary HTN similar to the Warburg
effect seen in cancer cells (28). It is possible that a similar mecha-
nism combined with obesity may be at work in arterial HTN, and a
considerable proportion of this effect is mediated by VF. Whereas
less than 20% of the effect of lactate on insulin resistance can be
explained by its effect on VF, 33% of its effect on SBP can be
explained by its effect on VF (Table 2). The pivotal role of lactate
highlights the importance of energy metabolism as the key link
between increased VF and higher risk of metabolic syndrome.
The strongest contribution via VF on SBP was seen, however, with
HWESASXX (39%). This peptide is linked to inflammation (29)
and is known to increase some of the biological actions of insulin-
like growth factors (30). This peptide has also been linked to intake
of antihypertensive drugs (31), hence the association with SBP could
have resulted from use of antihypertensive medication in those with
higher BP. However, the association between HWESASXX and
SBP remains significant after excluding individuals with a diagnosis
of HTN (b(SE)5 0.99 (0.23), P5 1.3 3 1025), so it appears to be
independent of medication use. The second metabolite identified,
androstenedione (4-androstenedione, 17-ketotestosterone) is a steroid
hormone (30). Increased levels of this compound have been reported
in childhood obesity, with adiposity and worse cardiometabolic pro-
file (32). Palmitic acid is the first fatty acid produced during lipo-
genesis. In humans, increases in dietary palmitate result in a
decrease in fat oxidation and daily energy expenditure, indicating
that it increases the risk of obesity and insulin resistance (33). This
is further supported by our own gene expression data which shows
that palmitate circulating levels are negatively correlated with perox-
isome proliferator-activated receptor-c gene expression levels in adi-
pose tissue (b5 0.08 (0.01) P 5 2.90 3 1029). A diet rich in
Figure 2 Association of selected metabolites with (A) systolic blood pressure (SBP), (B) diastolic blood pressure (DBP), and (C) visceral fat mass. The metabo-
lites are those previously reported to be associated with BP with P< 0.0001. The linear regression coefficients b and the 95% confidence intervals of the lin-
ear regression with the three traits adjusted for covariates are shown for each metabolite. P values are ‡P< 0.0001, ¶0.0001<P< 0.05, and n.s. P> 0.05.
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palmitic acid has been demonstrated to result in a BP-dependent
increase in arterial stiffness (34). However, less than 12% of the
effect of palmitic acid on SBP is due to its effect on VF mass.
Finally, the only compound associated significantly with both lower
BP and lower VF mass is phenylacetylglutamine. We have previ-
ously reported the protective role of phenylacetylglutamine on arte-
rial stiffness and Framingham cardiovascular risk in this same cohort
(35) and the negative correlation with VF indicates that this mole-
cule is a marker or is involved in lower risk of metabolic syndrome.
Metabolites associated with T2D but
not VF mass
We identified 12 metabolites associated with T2D but not with VF,
indicating that although VF mass has an important contribution to the
molecular pathogenesis of T2D, there are a number of molecular
markers strongly linked to T2D that are independent of VF mass. The
most significant metabolite associated with T2D but not associated
with VF is 1,5-anhydroglucitol, a well-known marker of short-term
glycemic control inversely proportional to glucose and is currently
proposed as a nontraditional marker in diabetes diagnosis, prognosis,
and management [see Parrinello and Selvin for review (36)].
We note some study limitations. First, the study sample consists of
women only, and some metabolites might be influenced by sex-
specific hormones. However, many of the metabolites identified in
this female-only sample with regards to T2D, specifically the
BCAAs, have been also identified in other studies where both men
and women were included (8,37) as associated with insulin resist-
ance and obesity, supporting the generalization of our results. Sec-
ond, because DXA measurements are not available in other Metabo-
lon metabolomics cohorts, we could not validate our VF results in
an independent sample. Furthermore, the cross-sectional nature of
our data does not allow us to draw conclusions as to whether the
metabolites identified are causative of VF/T2D or merely correlated
TABLE 4 Metabolites independently associated with VF (P<0.01 in backward linear regression) and their association with
T2D, HOMA-IR, and SBP
Metabolite name Subpathway
VF,
b (SE)
T2D,
OR (SE)
HOMA-IR,
b (SE) SBP, b (SE)
Asparagine Alanine and aspartate
metabolism
20.07 (0.01)b 1.16 (0.15) 20.06 (0.01)b 0.3 (20.19 to 0.79)
Creatine Creatine metabolism 0.08 (0.01)c 0.96 (0.12) 20.03 (0.02) 20.02 (20.49 to 0.45)
Glutamate Glutamate metabolism 0.13 (0.01)c 1.37 (0.19)a 0.14 (0.02)c 0.41 (20.09 to 0.91)
Serine Glycine, serine,
threonine metabolism
20.08 (0.01)c 0.85 (0.12) 20.1 (0.01)c 0.09 (20.4 to 0.59)
Phenylacetylglutamine Phenylalanine and tyrosine
metabolism
20.08 (0.01)c 0.97 (0.12) 0.03 (0.01) 21.04 (21.53 to 20.55)b
a-Hydroxyisovalerate Valine, leucine,
isoleucine metabolism
0.05 (0.01)b 1.53 (0.21)a 0.05 (0.02)a 1.31 (0.83 to 1.78)b
Glycerate Glycolysis, gluconeogenesis,
pyruvate metabolism
20.06 (0.01)b 0.95 (0.09) 20.04 (0.01)a 0.86 (0.35 to 1.38)a
Lactate Glycolysis, gluconeogenesis,
pyruvate metabolism
0.08 (0.01)c 1.84 (0.24)b 0.15 (0.01)c 1.51 (0.99 to 2.02)b
g-Tocopherol Tocopherol metabolism 0.06 (0.01)b 0.93 (0.12) 0.03 (0.02)a 0.7 (0.22 to 1.17)a
Hyodeoxycholate Bile acid metabolism 0.06 (0.01)b 1.47 (0.19)a 0.06 (0.02)a
Hexanoylcarnitine Carnitine metabolism 0.07 (0.01)b 0.6 (0.08)a 0.03 (0.02)a 1.48 (1.01 to 1.96)c
1-arachidonoylglycerophosphoinositola Lysolipid 0.09 (0.01)c 1.06 (0.14) 0.02 (0.01) 0.61 (0.15 to 1.08)a
Laurate (12:0) Medium-chain fatty acid 20.07 (0.01)b 0.69 (0.08)a 20.03 (0.01)a 1.52 (1.04 to 2)c
5a-androstan-3b,17b-diol disulfate Sterol/steroid 0.09 (0.01)c 1.28 (0.2) 0.04 (0.02)a
Urate Purine and
urate metabolism
0.11 (0.01)c 0.92 (0.13) 0.1 (0.02)c 1.09 (0.57 to 1.6)b
Cyclo(leu-pro) Dipeptide 0.06 (0.02)b 1.16 (0.14) 0.08 (0.02)b
g-glutamylvaline g-glutamyl 0.11 (0.01)c 1.41 (0.17)a 0.15 (0.02)c 0.45 (20.04 to 0.94)a
HWESASXXa Polypeptide 0.11 (0.01)c 1.28 (0.15)a 0.09 (0.02)b 0.94 (0.48 to 1.4)b
Catechol sulfate Benzoate metabolism 20.07 (0.01)b 1.2 (0.15) 0 (0.01) 20.61 (21.06 to 20.16)a
Stachydrine Food component/plant 20.06 (0.01)b 1.01 (0.12) 20.03 (0.02) 20.09 (20.56 to 0.37)
Data are presented as coefficient from linear regression (b) and standard error (SE) or as odds ratio (OR) and standard error.
aP< 0.05.
bP< 0.0001.
cP< 1 3 1028.
HOMA-IR, homeostasis model assessment-estimated insulin resistance; VF, visceral fat; T2D, type 2 diabetes; SBP, systolic blood pressure.
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with it. However, our results shed light on the TCA cycle as a key
pathway linking VF mass to T2D risk, which deserves further inves-
tigation. Finally, the observations derived from the mediation
approach shown here (proportion of association of metabolites due
to VF) are of purely statistical nature and do not necessarily imply a
functional connection.
Conclusion
The current study shows that of the metabolites associated with
T2D, those related to VF are all linked to energy metabolism, in
particular to glycolysis and the TCA cycle, and that on average 39%
of the association of these metabolites with insulin resistance is
mediated by their association with VF mass. We hypothesize that
reductions in VF mass may potentially result in improving the mito-
chondrial TCA cycle efficiency seen in patients with diabetes. This
is consistent with a recent therapeutic trial reporting that a very-low-
calorie diet can achieve nondiabetic fasting glucose levels in 50% of
patients while remaining off all other antidiabetic therapies (38).
The link between VF mass and BP appears to be related to energy
metabolism as well, via lactate and FFAs, but we find also a link
with steroids and inflammation.O
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